Effective use of fondaparinux in patient with unresponsiveness to nadroparin
Language English Country England, Great Britain Media print-electronic
Document type Case Reports, Journal Article
Grant support
Q25
Univerzita Karlova v Praze
PubMed
33277918
DOI
10.1111/jcpt.13328
Knihovny.cz E-resources
- Keywords
- anticoagulation, antithrombin, heparin resistance, low molecular weight heparin, pentasaccharide,
- MeSH
- Anticoagulants administration & dosage pharmacology therapeutic use MeSH
- Fondaparinux administration & dosage pharmacology therapeutic use MeSH
- Blood Coagulation drug effects MeSH
- Heparin, Low-Molecular-Weight administration & dosage pharmacology therapeutic use MeSH
- Humans MeSH
- Nadroparin administration & dosage pharmacology therapeutic use MeSH
- Aged MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- Anticoagulants MeSH
- Fondaparinux MeSH
- Heparin, Low-Molecular-Weight MeSH
- Nadroparin MeSH
WHAT IS KNOWN AND OBJECTIVE: Fondaparinux exhibits a similar mechanism of action as LMWH. Since both of these drugs bind to antithrombin and increase its affinity to factor Xa, fondaparinux is not expected to be an effective alternative anticoagulant to LMWH in case of LMWH resistance. CASE SUMMARY: We report on a case of effective anticoagulation using fondaparinux following total unresponsiveness to high doses of nadroparin administered twice daily, as confirmed via repeated anti-Xa measurements. The antithrombin levels were within the normal range. WHAT IS NEW AND CONCLUSION: To the best of our knowledge, this is the first report of the effective use of fondaparinux in the case of unresponsiveness to LMWH.
See more in PubMed
Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962.
Kang M, Alahmadi M, Sawh S, Kovacs MJ, Lazo-Langner A. Fondaparinux for the treatment of suspected heparin-induced thrombocytopenia: a propensity score-matched study. Blood. 2015;125(6):924-929.
Lau YC, Brown RA, Lip GY. Fondaparinux in atrial fibrillation - old dog, new tricks? Arch Cardiovasc Dis. 2015;108(2):85-87.
Cohen A, Stellbrink C, Le Heuzey J-Y, et al. Safety of Fondaparinux in transoesophageal echocardiography-guided Electric cardioversion of Atrial Fibrillation (SAFE-AF) study: a pilot study. Arch Cardiovasc Dis. 2015;108(2):122-131.
Stellbrink C, Nixdorff U, Hofmann T, et al. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial. Circulation. 2004;109(8):997-1003.
Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):e24S-e43S.
Cosmi B, Fredenburgh JC, Rischke J, Hirsh J, Young E, Weitz JI. Effect of nonspecific binding to plasma proteins on the antithrombin activities of unfractionated heparin, low-molecular-weight heparin, and dermatan sulfate. Circulation. 1997;95(1):118-124.
Krajewski KC, Smith K, Conwall K, Krajewski MP. Achievement of therapeutic anti-Xa levels in a proven heparin-resistant patient through the use of nontraditional high-dose enoxaparin. Ann Pharmacother. 2014;49(1):130-134.
Anderson JAM, Saenko EL. Editorial I: HYeparin resistance. BJA: Br J Anaesth. 2002;88(4):467-469.
Rollins KE, Trim NL, Luddington RJ, et al. Coagulopathy associated with massive cell salvage transfusion following aortic surgery. Perfusion. 2012;27(1):30-33.
Thota R, Ganti AK, Subbiah S. Apparent heparin resistance in a patient with infective endocarditis secondary to elevated factor VIII levels. J Thromb Thrombolysis. 2012;34(1):132-134.
